News | January 04, 2022
Combination of Covishield-Covaxin more effective: AIG hospital study
The first pilot study from India analyzing Covaxin-Covishield mixed doses
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
It plans to deliver over 300 million doses to the Indian government
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
Effectiveness of Covaxin against the Omicron variant is currently being studied
Subscribe To Our Newsletter & Stay Updated
